STL Index for: pregnancy
Topical retinoids are recommended as first-line therapy for most patients with acne. Tazarotene 0.045% lotion is a novel formulation that utilizes polymeric emulsion technology to improve tolerability and epidermal penetration.
Tazarotene 0.045% lotion is a novel formulation which utilizes polymeric emulsion technology to improve tolerability and epidermal penetration. Despite the lower concentration of tazarotene in the lotion formulation, which likely also contributes to improved tolerability, tazarotene 0.045% lotion is at least as effective as tazarotene 0.1% cream.
This index covers all articles published in Skin Therapy Letter Dermatology Edition articles in 2021. Articles are indexed by drug names, trade names and disease terms. Bold entries refer to major references.
A fixed combination halobetasol propionate and tazarotene lotion (HP/TAZ) was launched in Canada in 2020, to treat moderate to severe plaque psoriasis in adults. With the use of polymeric emulsion technology, there is uniform distribution of HP and TAZ and excipients on the skin and improved skin moisturization.
Certolizumab Pegol appears to offer a safe and effective psoriasis treatment for patients who are considering pregnancy, pregnant, or lactating based on its pharmacokinetics and available safety data.
Methotrexate has been an important agent in the management of dermatologic conditions for decades. Although first indicated for the treatment of psoriasis, MTX has been shown to be a successful treatment option for a wide array of skin diseases.
Practical guidelines for the management of Chronic Hand Dermatitis were published in the Skin Therapy Letter, Family Practice Edition (October 2016). This series of cases using Alitretinoin (Toctino®), is a follow on to that publication to put the guidelines into context.
This article reviews the mechanism of action, efficacy, bacterial coverage, and potential side effects for dalbavancin and oritavancin, both semisynthetic lipoglycopeptide antibiotics, and tedizolid, an oxazolidinone.
This articles discusses pregnancy-specific skin disorders: Pemphigoid gestationis, polymorphic eruption of pregnancy, atopic eruption of pregnancy, and intrahepatic cholestasis of pregnancy. Clinical presentation, potential for fetal complications, pathogenesis, diagnosis, and treatment are discussed.
Methotrexate has been used for over half a century to treat a wide spectrum of skin conditions. This article delves into research on the pharmacogenetic properties of the drug as well as the variety of skin conditions that Methotrexate is used to treat.
Urticaria and angioedema and some forms of this disorder may be increasing in both prevalence and severity due to changes in medications, environment and other factors. This review focuses on a rational approach to differential diagnosis and therapy of the most common forms of urticaria and angioedema.
External genital warts (EGW) are a common infection caused primarily by human papillomavirus (HPV) types 6 and 11. This article discusses the pathogenesis of EGW, impact on patients, therapeutics, vaccination, and other topics.
Pregnancy is characterized by multiple physiologic changes. Herein, we review the complicated relationships between psoriasis and pregnancy.
Solid organ transplant recipients have an increased incidence of skin cancer, resulting in significant morbidity and mortality post-transplantation. This article studies systemic retinoids, and other chemopreventative agents for high risk patients.
Pityriasis rosea is a common skin disorder in children and young adults. It is a self-limiting disease with symptoms that are typically mild and tolerable, however, there are times when treatment is warranted. In this paper, we review the available treatments for this skin disease.
Isotretinoin (Accutane) is a powerful drug, but one that has powerful side-effects. This article focuses on the side-effects that require monitoring as the symptoms may not be obvious to the patients.
Isotretinion will require monitoring by a doctor. While relatively rare, side-effects can be serious, and affect blood, bone, liver, neurologic, and muscle, and require periodic testing to ensure safety and healthy. It is also teratogenic, so pregnancy will also be a part in patient education.
Medications that are considered safe in pregnancy are available for the treatment of common dermatological disorders. Knowledge of these medications is important when considering treatment options for both pregnant patients, and women of childbearing potential.
Moderate-to-severe psoriasis is known to affect millions of people around the globe. This chronic disease substantially impacts patients by impairing their quality of life. The biologics are the newest and most effective therapeutic weapon in the treatment of moderate-to-severe psoriasis and psoriatic arthritis.
Bactroban (Mupirocin) and its potential side effects, safety profile, and risks are discussed. Precautions to be considered are also detailed.
Hyperpigmentation disorders of the skin are common and can be the source of significant psychosocial distress for patients. Topical applications are the mainstay of treatment and include phenols, retinoids, corticosteroids, and their combinations.
Cystic acne is characterized by the formation of cysts enclosing a mixture of keratin and sebum in varying proportions. It is the most severe of the four main types of acne, which are comedonal, papular, pustular, and cystic. Identification and treatment options are discussed.
Although the developing fetus was once considered protected from the outside world, we now know that it can potentially be affected by any medication given to the mother. Therapeutic options available for these patients will be discussed.
Photoaging is a multisystem degenerative process that involves the skin and the skin support systems, including the bone, cartilage, and subcutaneous compartments. These structures provide the architectural support for the dermis, epidermis, and stratum corneum.
Oral isotretinoin, since its introduction more than 20 years ago, has been and still is the 'gold standard' in the treatment of acne and its variants. This is the only approach to acne with the possibility of a permanent “cure” or long term remission.
Acne is a multifactorial disease of the pilosebaceous unit in the skin. Four contributing pathogenic factors need to be elucidated and include excess sebum production, follicular hyperkeratinization, colonization of the pilosebaceous unit by Propionibacterium acnes.
Use of medications by breast-feeding mothers is not uncommon. Information regarding the safety of common dermatological medications during lactation will be reviewed. Based on this information, treatment recommendations will be made.
Psoriasis, acne vulgaris and photoaging are common conditions. Tazarotene is a pro-drug of tazarotenic acid, a receptor-selective retinoid, which has shown efficacy in the treatment of these disorders. In the treatment of acne vulgaris, it has greater comedolytic activity than the currently available topical retinoids.
Rosacea is relatively common, typically occurring in individuals of Northern European and Celtic origin between 30 and 50 years of age. It is more common in women, but may be more severe in men. Currently there is no cure available for rosacea, but it can be controlled with topical and oral drug therapy.
US FDA Advisory Committee Meetings Held to Discuss Isotretinoin, Safety Issues and a New Accutane Formulation
There is no drug that has provided as much therapeutic benefit for 12 million acne patients as this retinoid has done in the past 18 years following its introduction. However, it is a retinoid and, therefore, a teratogen.
Topical acne treatment can positively benefit patients with acne. This review summarizes clinical and prescribing information on currently available topical agents. The efficacy of the medications included in this report is supported by properly designed randomized clinical trials.
Finasteride 1 mg (Propecia®, Merck) was approved by the US FDA December, 1997 for the treatment of male pattern hair loss (androgenetic alopecia, AGA) in men only. Safety and efficacy were demonstrated in men between 18 and 41 years of age with mild to moderate hair loss of the vertex and anterior mid-scalp area.